Leadership Changes At Evotec Chief Operating Officer To Step Down

Evotec SE has announced that Dr. Craig Johnstone, the company's Chief Operating Officer, will step down from his position and depart on December 31, 2024. Dr. Johnstone began his journey with Evotec in May 2012, serving as Senior Vice President for Drug Discovery and Innovation Efficiency. He was later appointed President and Site Head of Evotec (France) SAS in April 2015. In January 2017, he assumed the Global Head of Integrated Drug Discovery role and joined Evotec's Management Board as COO on January 1, 2019.

Prof. Dr. Iris Löw-Friedrich, Chairwoman of the Supervisory Board of Evotec, said in a statement, “In his 12-year tenure, Craig has been instrumental in shaping Evotec and Global Operations in particular. On behalf of Evotec’s Supervisory Board, I would like to express our sincere gratitude to Craig for his commitment to the company over the past decade. We wish Craig success in his future endeavours.”

“Thank you to all my talented colleagues across Evotec. Your passion for science and your commitment to excellence are humbling. I wish Evotec long-term success,” said Dr. Craig Johnstone, Chief Operating Officer of Evotec SE.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, commented, “On behalf of the Management Board, I would like to thank Craig for his leadership, passion, and dedication to Evotec for the past 12 years. We wish him all the very best for his next chapter.”

Until a revised organisational structure is established as part of the ongoing strategic review, the duties associated with the COO position will be temporarily managed by the Global Operations Leadership Team.